Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Globe Newswire•30/07/2026•06:20 ET
0
Whiz Insights
Get started
Create a free account to read the full story.